Clinical Trial Update: Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2) [Phase 2]

View source ↗

Summary

Phase 2 MATCH subprotocol study testing Erdafitinib for cancers with FGFR mutations or fusions. The trial status is active but not recruiting, and results were …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Solid Neoplasm

Drugs mentioned

• BALVERSA (erdafitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-06-18